Q-omics provides the consensus-scored NRCAM profile across patient tissues and cancer cell-line models. NRCAM expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, NRCAM is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, NRCAM protein abundance shows 28,472 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight COAD, THCA, and GBM as cancer lineages where NRCAM shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NRCAM — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NRCAM survival associations across molecular data types. NRCAM RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NRCAM RNA expression–survival associations across cancer types. High NRCAM expression shows unfavorable associations in COAD, STAD and LIHC, but favorable associations in HNSC, THCA and KIRC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify COAD as the clearest survival context for NRCAM RNA expression.
This table summarizes NRCAM tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 9. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for NRCAM. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NRCAM shows higher tumor expression in THCA, BLCA, LIHC, UCEC, LUSC and HNSC. The THCA box plot shows higher NRCAM RNA expression in tumor versus normal tissue (log2 FC = +2.558, t-test p < 0.001).
This table shows molecular features associated with NRCAM in patient tissues and cancer cell lines. In patient samples, NRCAM shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NRCAM RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SKIN.
